X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7993) 7993
Publication (1802) 1802
Book Review (202) 202
Book Chapter (80) 80
Newsletter (33) 33
Book / eBook (7) 7
Dissertation (7) 7
Conference Proceeding (3) 3
Magazine Article (3) 3
Newspaper Article (2) 2
Data Set (1) 1
Government Document (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5487) 5487
humans (5354) 5354
animals (3298) 3298
histone deacetylase inhibitors (2064) 2064
oncology (1945) 1945
cancer (1865) 1865
gene expression (1839) 1839
histone deacetylase (1719) 1719
mice (1703) 1703
epigenetics (1574) 1574
research (1544) 1544
dna methylation (1516) 1516
acetylation (1487) 1487
apoptosis (1411) 1411
male (1380) 1380
histone deacetylase inhibitors - pharmacology (1310) 1310
cell biology (1306) 1306
proteins (1262) 1262
histones - metabolism (1259) 1259
female (1256) 1256
article (1248) 1248
cell line, tumor (1199) 1199
biochemistry & molecular biology (1187) 1187
expression (1146) 1146
chromatin (1121) 1121
histone deacetylase inhibitor (1116) 1116
histone deacetylases - metabolism (1105) 1105
genetic aspects (1094) 1094
gene-expression (1088) 1088
methylation (946) 946
health aspects (926) 926
hydroxamic acids - pharmacology (905) 905
histones (874) 874
hematology (863) 863
medicine (851) 851
multidisciplinary sciences (848) 848
research article (838) 838
epigenesis, genetic (797) 797
physiological aspects (740) 740
transcription (717) 717
genetics & heredity (710) 710
care and treatment (705) 705
review (702) 702
epigenetic inheritance (676) 676
apoptosis - drug effects (672) 672
pharmacology & pharmacy (671) 671
valproic acid (670) 670
biology (656) 656
genes (654) 654
antineoplastic agents - pharmacology (639) 639
science (634) 634
deoxyribonucleic acid--dna (630) 630
analysis (620) 620
signal transduction (590) 590
activation (582) 582
histone deacetylase inhibitors - therapeutic use (571) 571
suberoylanilide hydroxamic acid (571) 571
genetics (554) 554
kinases (552) 552
differentiation (542) 542
leukemia (536) 536
cell cycle (527) 527
cells, cultured (523) 523
cells (517) 517
in-vivo (505) 505
tumors (505) 505
middle aged (502) 502
enzymes (494) 494
dna (491) 491
immunology (490) 490
cell line (488) 488
medicine, research & experimental (488) 488
acute myeloid-leukemia (487) 487
nf-kappa-b (481) 481
antineoplastic agents - therapeutic use (477) 477
inflammation (475) 475
transcription factors (467) 467
mutation (466) 466
stem cells (453) 453
rats (452) 452
inhibitors (449) 449
phosphorylation (448) 448
adult (447) 447
cell proliferation - drug effects (434) 434
enzyme inhibitors - pharmacology (434) 434
in-vitro (429) 429
promoter regions, genetic (426) 426
mice, inbred c57bl (424) 424
rodents (423) 423
aged (420) 420
chemotherapy (410) 410
hdac inhibitors (408) 408
development and progression (406) 406
histone deacetylases - genetics (404) 404
neurosciences (383) 383
gene expression regulation (379) 379
disease models, animal (369) 369
cell proliferation (365) 365
histone acetylation (354) 354
neoplasms - drug therapy (351) 351
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8088) 8088
Chinese (8) 8
German (4) 4
Japanese (3) 3
Korean (3) 3
Portuguese (2) 2
Russian (2) 2
French (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 1/2013, Volume 339, Issue 6116, pp. 211 - 214
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2/2013, Volume 110, Issue 7, pp. 2647 - 2652
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2017, Volume 35, Issue 11, pp. 1231 - 1238
Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone... 
HYDROXAMIC ACID | TRIAL | ONCOLOGY | SUNITINIB | LYMPHOMA | SORAFENIB | RECHALLENGE | Kidney Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Epigenesis, Genetic | Humans | Middle Aged | Histone Deacetylase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Benzofurans - administration & dosage | Male | Alanine Transaminase - blood | Benzofurans - blood | Fatigue - chemically induced | Vascular Endothelial Growth Factor A - genetics | Histone Deacetylase Inhibitors - blood | Benzofurans - pharmacokinetics | Young Adult | Histone Deacetylase Inhibitors - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Hydroxamic Acids - administration & dosage | Adult | Female | Acetylation | Carcinoma, Renal Cell - drug therapy | Neutropenia - chemically induced | Drug Resistance | Histone Deacetylase 2 - genetics | Hydroxamic Acids - blood | Gene Expression | Pyrimidines - administration & dosage | Vascular Endothelial Growth Factor A - blood | Treatment Outcome | Thrombocytopenia - chemically induced | Disease Progression | Hydroxamic Acids - pharmacokinetics | Disease-Free Survival | Maximum Tolerated Dose | Aspartate Aminotransferases - blood | Aged | Histones - metabolism | Kidney Neoplasms - drug therapy | Sulfonamides - administration & dosage | Drug Resistance, Neoplasm - drug effects | Index Medicus | ORIGINAL REPORTS
Journal Article
Neuropharmacology, ISSN 0028-3908, 01/2013, Volume 64, pp. 81 - 96
Long-term memory formation is known to be critically dependent upon gene expression in the brain. As a consequence, pharmacological enhancement of the... 
Chromatin | Cognitive enhancer | CREB | Epigenetic | Acetylation | Histone deacetylases | LONG-TERM-MEMORY | RUBINSTEIN-TAYBI-SYNDROME | TRANSCRIPTIONAL COACTIVATOR CBP | ELEMENT-BINDING PROTEIN | BETA-CATENIN | SYNAPTIC PLASTICITY | NEUROSCIENCES | ACETYLTRANSFERASE ACTIVITY | NEURITE OUTGROWTH | SMALL-MOLECULE INHIBITORS | PHARMACOLOGY & PHARMACY | GENE-TRANSCRIPTION | Embryo, Mammalian - drug effects | Nootropic Agents - metabolism | Neuronal Plasticity - drug effects | Drug Discovery - methods | Male | Neurons - cytology | Biphenyl Compounds - metabolism | Histone Deacetylase Inhibitors - blood | Embryo, Mammalian - metabolism | Prosencephalon - drug effects | Histone Deacetylase Inhibitors - pharmacokinetics | Biphenyl Compounds - pharmacology | Hydrazines - blood | Biphenyl Compounds - blood | Neurons - metabolism | Prosencephalon - metabolism | Neurons - drug effects | Animals, Newborn | Recombinant Proteins - metabolism | Dendrites - drug effects | Dendrites - metabolism | Nerve Tissue Proteins - antagonists & inhibitors | Biphenyl Compounds - pharmacokinetics | Hydrazines - pharmacology | Recombinant Proteins - antagonists & inhibitors | Histone Deacetylases - genetics | Mice, Inbred C57BL | Nootropic Agents - pharmacokinetics | Cells, Cultured | Histone Deacetylases - chemistry | Hydrazines - pharmacokinetics | Histone Deacetylases - metabolism | Mice, Transgenic | Nootropic Agents - blood | Nerve Tissue Proteins - genetics | Hydrazines - metabolism | Nerve Tissue Proteins - metabolism | Acetylation - drug effects | Animals | Embryo, Mammalian - cytology | Prosencephalon - cytology | Genes, Reporter - drug effects | Histone Deacetylase Inhibitors - pharmacology | Mice | Histones - metabolism | Histone Deacetylase Inhibitors - metabolism | Nootropic Agents - pharmacology | Genetic transcription | Cognition disorders | Neurons | Genes | Smart drugs and nutrients | acetylation | histone deacetylases | chromatin | epigenetic
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2012, Volume 30, Issue 6, pp. 2303 - 2317
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on... 
Marizomib | NPI-0052 | Medicine & Public Health | Lung cancer | Pancreatic cancer | Melanoma | Oncology | Pharmacology/Toxicology | Proteasome | APOPTOSIS | BORTEZOMIB | ONCOLOGY | PHARMACOLOGY & PHARMACY | CASPASE-8 | MODULATION | HDAC | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Pyrroles - pharmacokinetics | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Histone Deacetylase Inhibitors - blood | Pancreatic Neoplasms - drug therapy | Histone Deacetylase Inhibitors - pharmacokinetics | Lactones - blood | Lactones - pharmacokinetics | Lactones - administration & dosage | Pyrroles - administration & dosage | Hydroxamic Acids - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Proteasome Inhibitors - blood | Proteasome Inhibitors - pharmacokinetics | Carcinoma - drug therapy | Melanoma - metabolism | Hydroxamic Acids - blood | Proteasome Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Pyrroles - blood | Hydroxamic Acids - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Antineoplastic Agents - blood | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Carcinoma - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Combinations | Studies | Clinical trials | Pharmacology | Inhibitor drugs | Cancer therapies | Index Medicus
Journal Article
Science Translational Medicine, ISSN 1946-6234, 02/2016, Volume 8, Issue 326, pp. 326ra23 - 326ra23
Histone deacetylase inhibitors (HDACi) are approved for treating rare cancers and are of interest as potential therapies for neurodegenerative disorders. We... 
MEDICINE, RESEARCH & EXPERIMENTAL | MIGLUSTAT | TRANSPORT | SUBEROYLANILIDE HYDROXAMIC ACID | CHOLESTEROL ACCUMULATION | CYCLODEXTRIN | PURIFIED NPC1 PROTEIN | EVERY ORGAN | HISTONE DEACETYLASE INHIBITORS | BINDING | GAUCHER-DISEASE | CELL BIOLOGY | 2-Hydroxypropyl-beta-cyclodextrin | Inflammation - pathology | Niemann-Pick Disease, Type C - drug therapy | Liver - pathology | Histone Deacetylase Inhibitors - administration & dosage | Polyethylene Glycols - chemistry | Spleen - drug effects | RNA, Messenger - metabolism | Histone Deacetylase Inhibitors - blood | Niemann-Pick Disease, Type C - pathology | Inflammation - blood | Inflammation - complications | Liver - drug effects | Hydroxamic Acids - administration & dosage | Niemann-Pick Disease, Type C - blood | Purkinje Cells - drug effects | Spleen - pathology | Disease Models, Animal | Fibroblasts - metabolism | Hydroxamic Acids - blood | Purkinje Cells - metabolism | RNA, Messenger - genetics | Mutation - genetics | Blood-Brain Barrier - drug effects | Nerve Degeneration - complications | Disease Progression | Nerve Degeneration - pathology | Blood-Brain Barrier - metabolism | Blood-Brain Barrier - pathology | Animals | Nerve Degeneration - blood | beta-Cyclodextrins - chemistry | Fibroblasts - drug effects | Survival Analysis | Hydroxamic Acids - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Mice | Niemann-Pick Disease, Type C - complications | Purkinje Cells - pathology | Nerve Degeneration - drug therapy
Journal Article
Diabetologia, ISSN 0012-186X, 2/2018, Volume 61, Issue 2, pp. 389 - 398
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 9/2018, Volume 82, Issue 3, pp. 565 - 570
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 01/2015, Volume 75, Issue 1, pp. 87 - 95
Purpose This study assessed the pharmacokinetics and safety of oral panobinostat and its metabolite BJB432 in patients with advanced solid tumors and normal to... 
Panobinostat | Phase I | Medicine & Public Health | Pan-deacetylase inhibitor | Oncology | Cancer Research | Renal impairment | Pharmacology/Toxicology | Histone | MULTIPLE-MYELOMA | ADVANCED CANCER | DEACETYLASE INHIBITOR PANOBINOSTAT | ONCOLOGY | LBH589 | MALIGNANCIES | LYMPHOMA | PHARMACOLOGY & PHARMACY | Neoplasms - metabolism | Drugs, Investigational - adverse effects | Humans | Hydroxamic Acids - adverse effects | Middle Aged | Drugs, Investigational - pharmacokinetics | Drugs, Investigational - therapeutic use | Half-Life | Metabolic Clearance Rate | Antineoplastic Agents - therapeutic use | Drugs, Investigational - metabolism | Patient Dropouts | Histone Deacetylase Inhibitors - blood | Histone Deacetylase Inhibitors - pharmacokinetics | Neoplasms - complications | Indoles - metabolism | Neoplasm Grading | Renal Insufficiency - physiopathology | Antineoplastic Agents - adverse effects | Biotransformation | Aged, 80 and over | Adult | Renal Insufficiency - complications | Antineoplastic Agents - pharmacokinetics | Neoplasms - physiopathology | Kidney - physiopathology | Severity of Illness Index | Hydroxamic Acids - blood | Kidney - drug effects | Administration, Oral | Indoles - blood | Hydroxamic Acids - pharmacokinetics | Neoplasms - drug therapy | Hydroxamic Acids - metabolism | Indoles - adverse effects | Antineoplastic Agents - blood | Hydroxamic Acids - therapeutic use | Indoles - pharmacokinetics | Indoles - therapeutic use | Aged | Histone Deacetylase Inhibitors - therapeutic use | Drug Monitoring | Histone Deacetylase Inhibitors - adverse effects | Medicine, Experimental | Medical research | Care and treatment | Safety and security measures | Metabolites | Tumors
Journal Article
Biomedical Chromatography, ISSN 0269-3879, 01/2017, Volume 31, Issue 1, pp. np - n/a
Journal Article